Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BPMC Blueprint Medicines	$128.20 -0.1%	$111.90	$73.04 ▼ $128.52	$8.29B	0.89	1.32 million shs	2.32 million shs
HCM HUTCHMED	$15.69 +1.8%	$14.80	$11.51 ▼ $21.50	$2.69B	0.52	101,032 shs	47,966 shs
PTCT PTC Therapeutics	$49.15 +1.2%	$48.24	$29.02 ▼ $58.38	$3.85B	0.5	859,133 shs	1.06 million shs
RARE Ultragenyx Pharmaceutical	$39.46 +8.8%	$36.66	$29.59 ▼ $60.37	$3.43B	0.26	837,994 shs	1.82 million shs
ZLAB Zai Lab	$35.49 +0.9%	$33.66	$16.01 ▼ $44.34	$3.91B	0.99	910,166 shs	424,232 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BPMC Blueprint Medicines	-0.11%	-0.04%	+0.32%	+47.17%	+16.17%
HCM HUTCHMED	+1.82%	+1.36%	+15.37%	+2.89%	-8.89%
PTCT PTC Therapeutics	+1.15%	+0.53%	+0.66%	+5.18%	+61.73%
RARE Ultragenyx Pharmaceutical	+8.83%	+5.42%	+9.19%	+12.33%	-3.66%
ZLAB Zai Lab	+0.91%	-3.98%	+13.79%	-3.27%	+104.32%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BPMC Blueprint Medicines	1.5462 of 5 stars	2.1	4.0	0.0	2.2	0.8	0.6
HCM HUTCHMED	1.7721 of 5 stars	2.0	4.0	0.0	1.8	0.0	1.9
PTCT PTC Therapeutics	4.3316 of 5 stars	4.3	1.0	4.4	1.7	0.8	1.3
RARE Ultragenyx Pharmaceutical	3.9608 of 5 stars	3.5	1.0	3.8	2.1	2.5	0.6
ZLAB Zai Lab	3.3948 of 5 stars	3.4	5.0	0.0	3.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BPMC Blueprint Medicines	2.27	Hold	$128.06	-0.11% Downside
HCM HUTCHMED	2.00	Hold	$19.00	21.10% Upside
PTCT PTC Therapeutics	2.67	Moderate Buy	$65.00	32.25% Upside
RARE Ultragenyx Pharmaceutical	2.93	Moderate Buy	$87.00	120.48% Upside
ZLAB Zai Lab	2.80	Moderate Buy	$54.28	52.93% Upside

Current Analyst Ratings Breakdown

Latest ZLAB, HCM, BPMC, PTCT, and RARE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	ZLAB Zai Lab	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$73.00 ➝ $75.00
6/20/2025	RARE Ultragenyx Pharmaceutical	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$64.00
6/17/2025	BPMC Blueprint Medicines	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$143.00 ➝ $129.00
6/17/2025	PTCT PTC Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$80.00
6/5/2025	BPMC Blueprint Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$102.00 ➝ $129.00
6/5/2025	BPMC Blueprint Medicines	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$88.00 ➝ $129.00
6/4/2025	BPMC Blueprint Medicines	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold	$83.00 ➝ $129.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$132.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BPMC Blueprint Medicines	$508.82M	16.27	N/A	N/A	$4.70 per share	27.28
HCM HUTCHMED	$630.20M	4.34	$0.29 per share	53.65	$4.43 per share	3.54
PTCT PTC Therapeutics	$806.78M	4.83	N/A	N/A	($14.24) per share	-3.45
RARE Ultragenyx Pharmaceutical	$560.23M	6.66	N/A	N/A	$2.76 per share	14.30
ZLAB Zai Lab	$398.99M	9.88	N/A	N/A	$7.68 per share	4.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BPMC Blueprint Medicines	-$67.09M	-$2.47	N/A	197.23	N/A	-27.70%	-64.60%	-17.22%	7/30/2025 (Estimated)
HCM HUTCHMED	$37.73M	N/A	0.00	10.75	N/A	N/A	N/A	N/A	N/A
PTCT PTC Therapeutics	-$363.30M	$6.51	7.55	N/A	N/A	33.56%	-78.56%	32.11%	8/6/2025 (Estimated)
RARE Ultragenyx Pharmaceutical	-$569.18M	-$5.88	N/A	N/A	N/A	-93.04%	-186.49%	-36.81%	7/30/2025 (Estimated)
ZLAB Zai Lab	-$257.10M	-$2.49	N/A	N/A	N/A	-60.26%	-33.35%	-23.28%	8/5/2025 (Estimated)

Latest ZLAB, HCM, BPMC, PTCT, and RARE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	ZLAB Zai Lab	-$0.50	-$0.45	+$0.05	-$0.45	$118.40 million	$106.49 million
5/6/2025	Q1 2025	PTCT PTC Therapeutics	$0.85	$10.04	+$9.19	N/A	$437.16 million	$1.18 billion
5/6/2025	Q1 2025	RARE Ultragenyx Pharmaceutical	-$1.54	-$1.57	-$0.03	-$1.57	$145.98 million	$139.29 million
5/1/2025	Q1 2025	BPMC Blueprint Medicines	-$0.42	-$0.74	-$0.32	$0.01	$158.31 million	$149.41 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BPMC Blueprint Medicines	N/A	N/A	N/A	N/A	N/A
HCM HUTCHMED	N/A	N/A	N/A	N/A	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A
RARE Ultragenyx Pharmaceutical	N/A	N/A	N/A	N/A	N/A
ZLAB Zai Lab	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BPMC Blueprint Medicines	1.01	2.80	2.75
HCM HUTCHMED	0.08	2.83	2.70
PTCT PTC Therapeutics	N/A	3.89	3.85
RARE Ultragenyx Pharmaceutical	N/A	2.40	2.24
ZLAB Zai Lab	N/A	3.26	3.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BPMC Blueprint Medicines	N/A
HCM HUTCHMED	8.82%
PTCT PTC Therapeutics	N/A
RARE Ultragenyx Pharmaceutical	97.67%
ZLAB Zai Lab	41.65%

Insider Ownership

Company	Insider Ownership
BPMC Blueprint Medicines	4.21%
HCM HUTCHMED	3.60%
PTCT PTC Therapeutics	5.50%
RARE Ultragenyx Pharmaceutical	5.50%
ZLAB Zai Lab	4.96%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BPMC Blueprint Medicines	640	64.58 million	61.86 million	Optionable
HCM HUTCHMED	1,811	174.32 million	168.05 million	Not Optionable
PTCT PTC Therapeutics	1,410	79.26 million	74.90 million	Optionable
RARE Ultragenyx Pharmaceutical	1,310	94.54 million	89.34 million	Optionable
ZLAB Zai Lab	1,950	111.08 million	105.57 million	Optionable

ZLAB, HCM, BPMC, PTCT, and RARE Headlines

Recent News About These Companies

FY2026 EPS Estimates for Zai Lab Raised by Leerink Partnrs

4 hours ago | americanbankingnews.com

Leerink Partnrs Analysts Lift Earnings Estimates for Zai Lab

July 2 at 8:44 AM | marketbeat.com

Insider Selling: Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CEO Sells 6,918 Shares of Stock

July 2 at 5:40 AM | insidertrades.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CEO Sells $245,727.36 in Stock

July 1 at 6:05 PM | marketbeat.com

Amgen and Zai Lab’s trial of gastric cancer therapy meets primary endpoint

July 1 at 7:52 AM | finance.yahoo.com

Amgen, Zai Lab succeed in gastric cancer study

June 30 at 4:45 PM | msn.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Consensus Recommendation of "Moderate Buy" by Analysts

June 30 at 3:32 PM | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Price Target Raised to $75.00 at Leerink Partners

June 30 at 2:54 PM | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Shares Gap Up - Still a Buy?

June 30 at 12:14 PM | marketbeat.com

Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer

June 30 at 9:05 AM | businesswire.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CEO Sells $855,160.97 in Stock

June 30 at 4:09 AM | americanbankingnews.com

Oppenheimer Asset Management Inc. Makes New Investment in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

June 30 at 3:26 AM | marketbeat.com

Zai Lab (ZLAB) chief legal officer sells $212k in shares

June 29, 2025 | investing.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CFO Sells $96,647.75 in Stock

June 28, 2025 | insidertrades.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Shares Purchased by Mirae Asset Global Investments Co. Ltd.

June 28, 2025 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Stock Rating Lowered by Wall Street Zen

June 28, 2025 | americanbankingnews.com

Zai Lab (NASDAQ:ZLAB) Downgraded to Hold Rating by Wall Street Zen

June 27, 2025 | marketbeat.com

Insider Selling: Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CFO Sells 2,675 Shares of Stock

June 27, 2025 | marketbeat.com

Ying Du Sells 23,669 Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Stock

June 27, 2025 | marketbeat.com

Zai Lab Limited (ZLAB) - Yahoo Finance

June 27, 2025 | finance.yahoo.com

Cantor Fitzgerald Expects Reduced Earnings for Zai Lab

June 26, 2025 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZLAB, HCM, BPMC, PTCT, and RARE Company Descriptions

Blueprint Medicines NASDAQ:BPMC

$128.20 -0.14 (-0.11%)

Closing price 07/2/2025 04:00 PM Eastern

Extended Trading

$128.24 +0.04 (+0.03%)

As of 07/2/2025 05:08 PM Eastern

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

HUTCHMED NASDAQ:HCM

$15.69 +0.28 (+1.82%)

Closing price 07/2/2025 04:00 PM Eastern

Extended Trading

$15.98 +0.29 (+1.85%)

As of 04:00 AM Eastern

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

PTC Therapeutics NASDAQ:PTCT

$49.15 +0.56 (+1.15%)

Closing price 07/2/2025 04:00 PM Eastern

Extended Trading

$49.40 +0.25 (+0.51%)

As of 04:13 AM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Ultragenyx Pharmaceutical NASDAQ:RARE

$39.46 +3.20 (+8.83%)

Closing price 07/2/2025 04:00 PM Eastern

Extended Trading

$39.90 +0.44 (+1.10%)

As of 07/2/2025 06:22 PM Eastern

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

Zai Lab NASDAQ:ZLAB

$35.49 +0.32 (+0.91%)

Closing price 07/2/2025 04:00 PM Eastern

Extended Trading

$35.49 +0.00 (+0.01%)

As of 07/2/2025 05:03 PM Eastern

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time